MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - mnc pharma
- NOVARTIS - MYLAN (US)
NOVARTIS vs MYLAN (US) - Comparison Results
NOVARTIS Change
Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 NOVARTIS  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| NOVARTIS Mar-18 |
MYLAN Dec-18 |
NOVARTIS/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 758 | 3,383 | - | |
| Low | Rs | 579 | 1,862 | - | |
| Sales per share (Unadj.) | Rs | 228.4 | 1,556.9 | - | |
| Earnings per share (Unadj.) | Rs | 31.7 | 42.3 | - | |
| Cash flow per share (Unadj.) | Rs | 32.8 | 333.8 | - | |
| Dividends per share (Unadj.) | Rs | 10.00 | 0 | - | |
| Dividend yield (eoy) | % | 1.5 | 0 | - | |
| Book value per share (Unadj.) | Rs | 297.1 | 1,684.2 | - | |
| Shares outstanding (eoy) | m | 24.69 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.9 | 1.7 | 173.7% | |
| Avg P/E ratio | x | 21.1 | 62.0 | 33.9% | |
| P/CF ratio (eoy) | x | 20.4 | 7.9 | 259.7% | |
| Price / Book Value ratio | x | 2.2 | 1.6 | 144.5% | |
| Dividend payout | % | 31.5 | 0 | - | |
| Avg Mkt Cap | Rs m | 16,505 | 1,349,457 | 1.2% | |
| No. of employees | `000 | 0.7 | 35.0 | 1.9% | |
| Total wages/salary | Rs m | 1,445 | 0 | - | |
| Avg. sales/employee | Rs Th | 8,441.3 | 22,885.7 | 36.9% | |
| Avg. wages/employee | Rs Th | 2,163.6 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,173.1 | 621.4 | 188.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,639 | 801,001 | 0.7% | |
| Other income | Rs m | 1,718 | 0 | - | |
| Total revenues | Rs m | 7,357 | 801,001 | 0.9% | |
| Gross profit | Rs m | -63 | 207,269 | -0.0% | |
| Depreciation | Rs m | 25 | 149,979 | 0.0% | |
| Interest | Rs m | 55 | 38,525 | 0.1% | |
| Profit before tax | Rs m | 1,575 | 18,765 | 8.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 792 | -2,985 | -26.5% | |
| Profit after tax | Rs m | 784 | 21,750 | 3.6% | |
| Gross profit margin | % | -1.1 | 25.9 | -4.3% | |
| Effective tax rate | % | 50.3 | -15.9 | -315.9% | |
| Net profit margin | % | 13.9 | 2.7 | 511.8% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 9,522 | 447,278 | 2.1% | |
| Current liabilities | Rs m | 3,296 | 326,115 | 1.0% | |
| Net working cap to sales | % | 110.4 | 15.1 | 729.9% | |
| Current ratio | x | 2.9 | 1.4 | 210.6% | |
| Inventory Days | Days | 37 | 84 | 43.8% | |
| Debtors Days | Days | 28 | 93 | 30.5% | |
| Net fixed assets | Rs m | 46 | 155,381 | 0.0% | |
| Share capital | Rs m | 123 | 426 | 28.9% | |
| Net worth | Rs m | 7,336 | 866,536 | 0.8% | |
| Long term debt | Rs m | 0 | 935,271 | 0.0% | |
| Total assets | Rs m | 11,105 | 2,324,387 | 0.5% | |
| Interest coverage | x | 29.5 | 1.5 | 1,982.7% | |
| Debt to equity ratio | x | 0 | 1.1 | 0.0% | |
| Sales to assets ratio | x | 0.5 | 0.3 | 147.3% | |
| Return on assets | % | 7.6 | 2.6 | 291.3% | |
| Return on equity | % | 10.7 | 2.5 | 425.5% | |
| Return on capital | % | 22.2 | 3.2 | 699.0% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 1,610 | 166,448 | 1.0% | |
| From Investments | Rs m | 687 | -86,035 | -0.8% | |
| From Financial Activity | Rs m | -2,677 | -77,541 | 3.5% | |
| Net Cashflow | Rs m | -380 | 1,379 | -27.5% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.08 Rs / USD
Compare NOVARTIS With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare NOVARTIS With: PLETHICO PHARMA ABBOTT INDIA FDC LTD. ORCHID PHARMA LTD SUVEN LIFESCIENCES
|
| |
Today's Market
Indian Indices Trade on a Volatile Note; Healthcare and Banking Stocks Witness Buying(12:30 pm)
Share markets in India are presently trading marginally higher. Sectoral indices are trading mixed with stocks in the metal sector and IT sector.
Related Views On News
NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)
Aug 13, 2019 | Updated on Aug 13, 2019For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
My 3 Best Small-cap Stocks to Get Rich in this Market Rebound (Profit Hunter)
Oct 14, 2019This is once in a decade opportunity to make a killing from smallcap rebound.
Buy these 3 Stocks for Rebound Riches
Oct 18, 2019Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...
Two Stocks to Buy in the Great Indian Festival (Profit Hunter)
Oct 11, 2019Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.
The One Stock I Like in this Market (The 5 Minute Wrapup)
Oct 10, 2019There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?
5 Smart Money Stocks to Profit from the Market Rebound (The 5 Minute Wrapup)
Oct 11, 2019Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.
More|
| |
NOVARTIS SHARE PRICE
Oct 22, 2019 01:57 PM
TRACK NOVARTIS
- Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON NOVARTIS
NOVARTIS 5-YR ANALYSIS
COMPARE NOVARTIS WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.